Do We Still Love This 10/10 Stock?

[View in browser]( [The Spill Logo] Proprietary Data Insights Financial Pros’ Top Consumer Healthcare Stock Searches in the Last Month Rank Name Searches #1 'CVS Corp 117 #2 'Walgreens Boots Alliance 88 #3 'Rite Aid Corp 32 #4 'Cigna Corp 17 #5 'Petmed Express Inc 4 #ad [It's time you learn about Alternative Investments!]( Brought to you by [Atakama]( [Earn 23% Annual Yield by investing in a lawsuit]( [Atakama - Earn 23% Annual Yield by investing in a lawsuit]( Finance a $700,000,000 lawsuit against a $76 billion asset management firm and earn 23% Annual Yield* on your investment. This investment is within a class of investments often called Litigation Finance. Litigation finance is an exclusive asset category, usually reserved for ultra-high net worth individuals and institutional investors - but is now being offered to the public. To learn more visit . There is limited availability, but you can join the waitlist today. [Learn More]( *There are no guarantees that any investment scenarios may achieve intended results. Do We Still Love This 10/10 Stock? So, you thought CVS (CVS) was just that ubiquitous corner pharmacy where you grab toothpaste and pick up Aunt Sally's medications? Think again. In early March, [we rated CVS a 10/10.]( As the top consumer healthcare stock amongst financial pros, we loved the holistic transformation the company embarked on. Once a simple retail pharmacy chain, CVS aimed to become a fully integrated healthcare provider, acquiring Aetna in 2018 for $70 billion. Yet, the stock has dropped nearly 20% since then as it slid into Q1 earnings and remained there through the present. So, do we stand by our rating? Yes, and here’s why. CVS’ Business CVS embarked on an ambitious plan to branch beyond its pharmacy stores to become a benefits manager and provider. The $70 billion acquisition of Aetna in 2018 was the largest acquisition of that type in history. You can think of CVS as your one-stop shop for everything from prescription drugs to beauty products and healthcare insurance. Fun fact: they cater to a staggering 100 million customers per year, and their mammoth team of 300,000 employees makes it all possible. Today, the company reports in three segments: - Pharmacy Services (47% of total revenues) - This is where CVS becomes the middleman for your meds. The segment delivers pharmacy benefit management, specialty pharmacy, and mail order pharmacy services to a swath of customers from employers to governments. - Retail/LTC (32% of total revenues) - Beyond just dispensing prescriptions, this segment sells general merchandise both in stores and online. And don't forget the retail clinics and long-term care pharmacy services. - Health Care Benefits (21% of total revenues) - The segment that holds Aetna offers health insurance products for everyone from your boss to Uncle Sam. In its Q2 2023 earnings release, CVS achieved net income of $2.8 billion, slightly down from the same period last year but pushed revenues up by 11% to a cool $72.6 billion. The company appears to be struggling with its Medicare, which makes up 25% of its total revenues. Its Q2 utilization rate was higher than expected, driving up costs. Plus, the reimbursement rates are a big question mark going forward. California’s Blue Shield recently dropped CVS as its benefits provider in favor of a new approach to negotiating drug prices directly with manufacturers. Financials [Financials] Source: Stock Analysis Revenue growth hasn’t been a problem for CVS, especially with its acquisition of Aetna. The focus now is on the margins as gross margins fell over the last few years, taking down operating and profit margins. However, many costs were non-cash as the free-cash-flow margin remained relatively stable. CVS took on a lot of debt to acquire Aetna. And so far, it hasn’t done much to pay down the $80+ billion. That’s a hefty amount, considering they only generate $20 billion in cash from operations annually. And interest runs at a whopping $2.4 billion annually. So, it’s fair to say their cost-cutting measures are needed to alleviate some of the pressures on the bottom line. We do question whether should continue to pay their almost 4% dividend alongside their share repurchase program, which combined cost them almost $7 billion annually. Pushing that back towards debt repayment may be more appropriate. Valuation [Valuation] Source: Stock Analysis We compared CVS to other drug stores such as Walgreens (WBA) as well as health insurer Cigna (CI) to get a blended view. CVS trades at the lowest price-to-cash flow of the group and close to the lowest non-GAAP price-to-earnings ratio. It’s certainly cheap. But is it a value trap? Growth [Growth] Source: Seeking Alpha Revenue growth is expected to slow dramatically for CVS, dropping below double digits. However, the company is expected to improve its EBITDA and EPS going forward, a positive sign of the ongoing transformation. Only CI is expected to put up decent growth in these same categories going forward. Profitability [Profit] Source: Seeking Alpha CVS doesn’t have the best gross margin. But its EBIT margin is near the top, as is its free cash flow margin. We’d like to see these improve to become top of the pack within the following year. [The Most Researched Tickers [FREE REPORT]]( Once every quarter, we compile millions of Financial Professional and Retail Investor's stock searches across our 100+ financial sites. We reserve this exclusive report for our newsletter subscribers so you can learn about the stocks and industries that you should keep an eye on. This info can help you decide what to do in your portfolio – so you can protect the money you have and generate bigger gains. [Click here now to download the FREE Trackstar Report.]( Our Opinion 10/10 We’re sticking with our call as nothing has materially changed. Transformations of this magnitude take time. And we expect there to be hiccups along the way. However, the long-term outlook for the company remains bullish. Plus, the company has plenty of cash to maneuver when needed. [-facebook-share]( [-twitter-share]( [-linkedin-share]( [-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D590602?utm_medium=ic-nl&utm_source=112463 ) News & Insights Just Spilled - [Financial Pros Are Eyeballing THIS Dividend ETF]( - [Investing made easy with a daily quick read]( - [Financial Pros Backdoor Play on AWS]( - [How Lowes Took the Top Spot Amongst Financial Pros]( [News & Insights-facebook-share]( [News & Insights-twitter-share]( [News & Insights-linkedin-share]( [News & Insights-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D590602?utm_medium=ic-nl&utm_source=112463 ) [We want to hear from you. Let us know your thoughts by clicking here]( [Ads] [InvestingChannel Logo](#) Follow us on: [Facebook Logo]( [LinkedIn Logo]( [Twitter Logo]( [Instagram Logo]( To ensure delivery of all emails, [allow us on your list](. Manage your subscriptions with our [preference center](. [Unsubscribe here.]( View our privacy policy [here](. Copyright ©2023 InvestingChannel. All rights reserved. 1325 Avenue of the Americas, Floor 27 & 28 New York, New York 10019 Disclaimer: This is not investment advice. This InvestingChannel, Inc., newsletter is for information purposes only and is based on opinion. Futures, forex, stock, and options trading are not appropriate for all investors. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or methodology has ever been developed that can ensure returns or eliminate losses. InvestingChannel, Inc., makes no representation or implication that using any of the methodologies or systems in this newsletter will generate returns or insure against losses. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions. [Link](